Case todayBrokenLate SEC filing · Nov 17, 2026The case · mixed · Nov 17, 2026Own ACBM if ACBM is not a durable operating compounder today; it is a financed-restart option on a dormant cordyceps/wellness distributor whose core problems are customers, suppliers, leadership, and cash.4 conditions2 strengthening · 1 holding · 1 weakeningNext resultsNot scheduledNo date filed yet

ACBM at a glance

The past year

Chart

+3614.3% $0.03, close Nov 13

From the highest close
At the high
Vs the 200-day average
+2.0%
Nov 12, 2025Daily close, Acro Biomedical Co.Nov 13, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 11 – Nov 17

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

ACBM price history

Latest price—Today— (—)
ACBM —S&P 500 —Since first plotted close

Loading ACBM and S&P 500 price history…

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • External funding is the gating input for any business restart because Acro has no self-funding operating base and says it needs significant funding to implement its preliminary business plan.StrengtheningMateriality: High

    GAAP cash was only $4,098 at December 31, 2025, despite the company needing funds to recommence operations. If funding arrives on workable terms, ACBM has a chance to buy inventory and resume marketing; if it does not, the operating story cannot restart.

    Watch: A binding non-dilutive loan facility or customer prepayment large enough to fund inventory purchases and marketing.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP cash was only $4,098 at December 31, 2025, despite the company needing funds to recommence operations.

    Open source ↗
  • The prior demand channel has to be rebuilt, not merely reactivated, because historical sales were concentrated in a few customers and all sales were made by one part-time CEO who has resigned.WeakeningMateriality: High

    GAAP annual revenue was $0 in FY2023, $0 in FY2024, and $0 in FY2025. A restart requires new paying customers and a sales function; otherwise revenue remains an artifact of old relationships rather than a repeatable business.

    Watch: A signed purchase order from a new unrelated customer for cordyceps or complementary wellness products.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue was $0 in FY2023, $0 in FY2024, and $0 in FY2025.

    Open source ↗
  • Durable value requires Acro to secure differentiated products, exclusive supply, or proprietary development, because the current described model is mainly resale of supplier-sourced cordyceps products with no proven pricing power.HoldingMateriality: Medium

    GAAP annual gross profit was $259,500 in FY2021 and $140,500 in FY2022, then $0 in FY2023 after sales stopped. If Acro remains an undifferentiated reseller, any sales revival could carry weak margins and little defensible value; differentiation would make the restart more investable.

    Watch: An exclusive supplier agreement for cordyceps or another wellness product that gives Acro protected distribution economics.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual gross profit was $259,500 in FY2021 and $140,500 in FY2022, then $0 in FY2023 after sales stopped.

    Open source ↗
  • Any commercial restart is likely to be constrained by dilution risk because Acro has negative book equity, limited cash, no active public quotation, and says equity financing may be difficult and dilutive.StrengtheningMateriality: Medium

    GAAP stockholders’ equity was negative $386,964 at December 31, 2025. Even a successful operating restart may not create per-share value if the capital required to restart the business is raised on punitive terms.

    Watch: A non-dilutive financing package or customer-funded working-capital arrangement.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP stockholders’ equity was negative $386,964 at December 31, 2025.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

External funding is the gating input for any business restart because Acro has no self-funding operating base and says it needs significant funding to implement its preliminary business plan. If funding arrives on workable terms, ACBM has a chance to buy inventory and resume marketing; if it does not, the operating story cannot restart.

The prior demand channel has to be rebuilt, not merely reactivated, because historical sales were concentrated in a few customers and all sales were made by one part-time CEO who has resigned. A restart requires new paying customers and a sales function; otherwise revenue remains an artifact of old relationships rather than a repeatable business.

Durable value requires Acro to secure differentiated products, exclusive supply, or proprietary development, because the current described model is mainly resale of supplier-sourced cordyceps products with no proven pricing power. If Acro remains an undifferentiated reseller, any sales revival could carry weak margins and little defensible value; differentiation would make the restart more investable.

Any commercial restart is likely to be constrained by dilution risk because Acro has negative book equity, limited cash, no active public quotation, and says equity financing may be difficult and dilutive. Even a successful operating restart may not create per-share value if the capital required to restart the business is raised on punitive terms.

All standing thesis claims
Original report summary

ACBM is not a durable operating compounder today; it is a financed-restart option on a dormant cordyceps/wellness distributor whose core problems are customers, suppliers, leadership, and cash.

Evidence assessed Nov 17, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Acro Biomedical Co.

Where the evidence on Acro Biomedical Co. disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.

Bull case: what the evidence supports

  • External funding is the gating input for any business restart because Acro has no self-funding operating base and says it needs significant funding to implement its preliminary business plan.

    sec.gov ↗

  • Durable value requires Acro to secure differentiated products, exclusive supply, or proprietary development, because the current described model is mainly resale of supplier-sourced cordyceps products with no proven pricing power.

    sec.gov ↗

  • Any commercial restart is likely to be constrained by dilution risk because Acro has negative book equity, limited cash, no active public quotation, and says equity financing may be difficult and dilutive.

    sec.gov ↗

Bear case: what the evidence questions

  • The prior demand channel has to be rebuilt, not merely reactivated, because historical sales were concentrated in a few customers and all sales were made by one part-time CEO who has resigned.

    sec.gov ↗

Thesis-Break Engine

What has broken in Acro Biomedical Co.’s thesis

Each break OptimistFi flagged on Acro Biomedical Co., dated — with what has historically followed the same kind of break across the market, not a forecast for Acro Biomedical Co..

peers+16%-43%-12%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -12% path vs comparable companies over six months, inside the middle-half range (+16% to -43%). A base rate, not a forecast.
  • Late SEC filingcondition set before this filing

    Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.

  • CEO / officer changecondition set before this filing

    Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.

Early warning

The break condition read on the trailing twelve months through Acro Biomedical Co.’s latest quarterly report, ahead of the annual figure it is written on.

  • Revenue decline, trailing 12 months

    Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.

Several kinds of break have stacked on Acro Biomedical Co. at once. A cluster is a stronger read than any one signal alone.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Director or principal officer change.

    Acro Biomedical Co. filed an SEC 8-K on 2026-09-02: Director or principal officer change. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A binding non-dilutive loan facility or customer prepayment large enough to fund inventory purchases and marketing.
  • A signed purchase order from a new unrelated customer for cordyceps or complementary wellness products.
  • An exclusive supplier agreement for cordyceps or another wellness product that gives Acro protected distribution economics.
  • A non-dilutive financing package or customer-funded working-capital arrangement.

ACBM news

Loading headlines…

Financial statements

ACBM income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.